Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.

View in: PubMed

subject areas

Antibodies
Antibodies, Monoclonal
Antibody Formation
Crohn Disease
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Gastrointestinal Agents
Humans
Infliximab
Infusions, Intravenous
Male
Probability
Reference Values
Risk Assessment
Severity of Illness Index
Treatment Outcome

authors with profiles

Stephen B. Hanauer